Roivant pivot: FDA fast-tracks dermatomyositis drug as lead asset misses study goals
Roivant Sciences (NASDAQ:ROIV) provided a comprehensive clinical and regulatory update on Thursday, April 2, 2026, revealing a bifurcated path for its most advanced autoimmune programs.








_1373502_640x360_2494756419591-640x360.webp&w=3840&q=75)
